J Korean Med Sci.  1990 Jun;5(2):75-83. 10.3346/jkms.1990.5.2.75.

Nodular hepatocellular carcinoma: treatment with intraarterial injection of I-131 Lipiodol

Affiliations
  • 1Department of Radiology, Yonsei University College of Medicine, Seoul, Korea.

Abstract

Twenty four patients with hepatocellular carcinoma who refused surgery or had unresectable tumor ranging 2.5 to 8.0 cm in size were treated with intrahepatic arterial injection of iodine-131-labeled iodized oil (I-131 Lipodol) in an attempt to achieve internal radiation of tumor. 555-2,220 MBq in 3-8 ml of I-131 Lipiodol was injected into the hepatic artery or proximal to the tumor feeding vessel depending on the tumor size. Tumor size reduction was observed in 88.9% of tumor smaller than 4.0 cm in diameter, 65.5% between 4.1 to 6.0 cm, and 25.0% of larger than 6.1cm, respectively. The tumor size reduction was corresponded to the gradual drop of serum AFP levels, decreased uptake on gallium-67 scintigraphy, and devascularization on follow-up angiography. Tumors having significant A-V shunts revealed further tumor growth. Adverse reactions from the treatment include fever, mild abdominal pain, nausea and elevation of transaminases. These have been mild and well-tolerated by the patients. This method was able to provide long term local control without complications related to thyroid, lung, GI tract and bone marrow.

Keyword

Liver neoplasms therapy; Iodine and iodine compounds radioactive; Liver neoplasms radionuclide studies; Radionuclides therapeutic

MeSH Terms

Adult
Aged
Angiography
Carcinoma, Hepatocellular/radionuclide imaging/*therapy
Follow-Up Studies
Humans
Infusions, Intra-Arterial
Iodine Radioisotopes/therapeutic use
Iodized Oil/adverse effects/*therapeutic use
Liver Neoplasms/radionuclide imaging/*therapy
Male
Middle Aged
Iodine Radioisotopes
Iodized Oil
Full Text Links
  • JKMS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr